Compare THH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | PPBT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 45.3M |
| IPO Year | N/A | 2014 |
| Metric | THH | PPBT |
|---|---|---|
| Price | $0.41 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 223.2K | 54.2K |
| Earning Date | 03-31-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.41 |
| 52 Week High | $56.26 | $5.18 |
| Indicator | THH | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 66.76 |
| Support Level | N/A | $0.57 |
| Resistance Level | $0.55 | $5.18 |
| Average True Range (ATR) | 0.05 | 0.42 |
| MACD | 0.28 | -0.09 |
| Stochastic Oscillator | 20.77 | 15.69 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.